|Day Low/High||68.92 / 69.94|
|52 Wk Low/High||63.76 / 89.54|
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the Order of Australia in recognition of his "distinguished service to medical...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy, with responsibility for Gilead's corporate development, alliance management, competitive intelligence,...
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
Kite, a Gilead Company (Nasdaq: GILD), today announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in...
Kite, a Gilead Company (Nasdaq: GILD), today announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting...
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.
Following up on President Trump's drug pricing speech last week, the FDA posted a list of 39 name-brand drug firms that are allegedly making life tough on generic drug companies.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.
Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe.
After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
The most recent short interest data has been released for the 04/30/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Harish M.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2018.
I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.
Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily's Immunoscape platform to identify and better understand the immunological basis of three common and serious...
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization...
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.